FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306291521> ?p ?o ?g. }

• W4306291521 endingPage "161" @default.
• W4306291521 startingPage "157" @default.
• W4306291521 abstract "Gastric pH changes by proton-pump-inhibitors (PPIs) were found to affect progression-free survival (PFS) in metastatic breast cancer (mBC) patients treated with palbociclib. The current study was aimed at investigating whether the same effect could occur in patients treated with ribociclib.Patients with hormone-positive/HER-2-negative mBC candidates for first-line treatment with ribociclib were enrolled in this retrospective-cohort study. Patients were classified as no concomitant PPIs or concomitant PPIs; PPI administration covered the entire or not less than 2/3 of treatment with ribociclib. All clinical interventions were made according to clinical practice.A total of 128 patients were consecutively enrolled in the study; 78 belonged to the no concomitant PPIs group and 50 to the concomitant PPIs group. One hundred and six patients were endocrine-sensitive and received ribociclib and letrozole, while 22 were endocrine-resistant and were treated with ribociclib and fulvestrant. The most prescribed PPI was lansoprazole. According to PFS, patients taking PPIs had a PFS almost superimposable to those assuming ribociclib and endocrine therapy alone (35.3 vs. 49.2 months, p = 0.594). No difference in PFS was observed in estrogen-sensitive or estrogen-resistant mBC in the presence or absence of concomitant PPI treatment (p = 0.852). No correlation with adverse events was found including grade>2 hematological toxicities.The present study supports the hypothesis that the concomitant use of PPIs does not compromise the efficacy of ribociclib in a real-life setting." @default.
• W4306291521 created "2022-10-15" @default.
• W4306291521 creator A5009740901 @default.
• W4306291521 creator A5018910230 @default.
• W4306291521 creator A5022888812 @default.
• W4306291521 creator A5030848899 @default.
• W4306291521 creator A5040416185 @default.
• W4306291521 creator A5041162956 @default.
• W4306291521 creator A5041223140 @default.
• W4306291521 creator A5046176016 @default.
• W4306291521 creator A5046867244 @default.
• W4306291521 creator A5051572125 @default.
• W4306291521 creator A5059568057 @default.
• W4306291521 creator A5061818416 @default.
• W4306291521 creator A5068107707 @default.
• W4306291521 creator A5069349994 @default.
• W4306291521 creator A5071060598 @default.
• W4306291521 creator A5072492254 @default.
• W4306291521 creator A5076579102 @default.
• W4306291521 creator A5079091838 @default.
• W4306291521 creator A5079718032 @default.
• W4306291521 creator A5083693387 @default.
• W4306291521 date "2022-12-01" @default.
• W4306291521 modified "2023-09-24" @default.
• W4306291521 title "Concomitant administration of proton pump inhibitors does not significantly affect clinical outcomes in metastatic breast cancer patients treated with ribociclib" @default.
• W4306291521 cites W2290950904 @default.
• W4306291521 cites W2528767298 @default.
• W4306291521 cites W2552099557 @default.
• W4306291521 cites W2557776926 @default.
• W4306291521 cites W2606840735 @default.
• W4306291521 cites W2620993107 @default.
• W4306291521 cites W2763875663 @default.
• W4306291521 cites W2769143729 @default.
• W4306291521 cites W2802776309 @default.
• W4306291521 cites W2804105316 @default.
• W4306291521 cites W2805575723 @default.
• W4306291521 cites W2896846857 @default.
• W4306291521 cites W2922159934 @default.
• W4306291521 cites W2948069739 @default.
• W4306291521 cites W3092581914 @default.
• W4306291521 cites W3134739132 @default.
• W4306291521 cites W3167855488 @default.
• W4306291521 cites W3174209195 @default.
• W4306291521 cites W3197850311 @default.
• W4306291521 cites W4221085715 @default.
• W4306291521 cites W4229026463 @default.
• W4306291521 cites W4239051461 @default.
• W4306291521 doi "https://doi.org/10.1016/j.breast.2022.10.005" @default.
• W4306291521 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36283134" @default.
• W4306291521 hasPublicationYear "2022" @default.
• W4306291521 type Work @default.
• W4306291521 citedByCount "2" @default.
• W4306291521 countsByYear W43062915212023 @default.
• W4306291521 crossrefType "journal-article" @default.
• W4306291521 hasAuthorship W4306291521A5009740901 @default.
• W4306291521 hasAuthorship W4306291521A5018910230 @default.
• W4306291521 hasAuthorship W4306291521A5022888812 @default.
• W4306291521 hasAuthorship W4306291521A5030848899 @default.
• W4306291521 hasAuthorship W4306291521A5040416185 @default.
• W4306291521 hasAuthorship W4306291521A5041162956 @default.
• W4306291521 hasAuthorship W4306291521A5041223140 @default.
• W4306291521 hasAuthorship W4306291521A5046176016 @default.
• W4306291521 hasAuthorship W4306291521A5046867244 @default.
• W4306291521 hasAuthorship W4306291521A5051572125 @default.
• W4306291521 hasAuthorship W4306291521A5059568057 @default.
• W4306291521 hasAuthorship W4306291521A5061818416 @default.
• W4306291521 hasAuthorship W4306291521A5068107707 @default.
• W4306291521 hasAuthorship W4306291521A5069349994 @default.
• W4306291521 hasAuthorship W4306291521A5071060598 @default.
• W4306291521 hasAuthorship W4306291521A5072492254 @default.
• W4306291521 hasAuthorship W4306291521A5076579102 @default.
• W4306291521 hasAuthorship W4306291521A5079091838 @default.
• W4306291521 hasAuthorship W4306291521A5079718032 @default.
• W4306291521 hasAuthorship W4306291521A5083693387 @default.
• W4306291521 hasBestOaLocation W43062915212 @default.
• W4306291521 hasConcept C121608353 @default.
• W4306291521 hasConcept C126322002 @default.
• W4306291521 hasConcept C143998085 @default.
• W4306291521 hasConcept C2775930923 @default.
• W4306291521 hasConcept C2776409635 @default.
• W4306291521 hasConcept C2777176818 @default.
• W4306291521 hasConcept C2778715759 @default.
• W4306291521 hasConcept C2779384505 @default.
• W4306291521 hasConcept C2779744173 @default.
• W4306291521 hasConcept C2780482068 @default.
• W4306291521 hasConcept C530470458 @default.
• W4306291521 hasConcept C71924100 @default.
• W4306291521 hasConcept C90924648 @default.
• W4306291521 hasConceptScore W4306291521C121608353 @default.
• W4306291521 hasConceptScore W4306291521C126322002 @default.
• W4306291521 hasConceptScore W4306291521C143998085 @default.
• W4306291521 hasConceptScore W4306291521C2775930923 @default.
• W4306291521 hasConceptScore W4306291521C2776409635 @default.
• W4306291521 hasConceptScore W4306291521C2777176818 @default.
• W4306291521 hasConceptScore W4306291521C2778715759 @default.
• W4306291521 hasConceptScore W4306291521C2779384505 @default.
• W4306291521 hasConceptScore W4306291521C2779744173 @default.
• W4306291521 hasConceptScore W4306291521C2780482068 @default.

• next